163 related articles for article (PubMed ID: 37171300)
21. SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Zhao J; Yu X; Huang D; Ma Z; Gao B; Cui J; Chu Q; Zhou Q; Sun M; Day D; Wu J; Pan H; Wang L; Voskoboynik M; Wang Z; Liu Y; Li H; Zhang J; Peng Y; Wu YL
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36808075
[TBL] [Abstract][Full Text] [Related]
22. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
23. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
[TBL] [Abstract][Full Text] [Related]
24. [Regression of cutaneous basal cell and squamous cell carcinoma under pembrolizumab].
Delaitre L; Martins-Héricher J; Truchot E; Denis D; Prophette B; Maillard H; Bénéton-Benhard N
Ann Dermatol Venereol; 2020 Apr; 147(4):279-284. PubMed ID: 31879092
[TBL] [Abstract][Full Text] [Related]
25. PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change.
Tsai KK; Khurana N; McCalmont T; Daud A; Bastian B; Yeh I
J Natl Compr Canc Netw; 2019 Jul; 17(7):778-783. PubMed ID: 31319387
[TBL] [Abstract][Full Text] [Related]
26. The Landmark Series: Non-melanoma Skin Cancers.
Lee AY; Berman RS
Ann Surg Oncol; 2020 Jan; 27(1):22-27. PubMed ID: 31549317
[TBL] [Abstract][Full Text] [Related]
27. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
[TBL] [Abstract][Full Text] [Related]
28. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC).
Liu SY; Wu YL
Expert Opin Investig Drugs; 2020 Dec; 29(12):1355-1364. PubMed ID: 33044117
[TBL] [Abstract][Full Text] [Related]
29. Pharmacologic treatment options for advanced epithelial skin cancer.
Soura E; Chasapi V; Stratigos AJ
Expert Opin Pharmacother; 2015; 16(10):1479-93. PubMed ID: 26027692
[TBL] [Abstract][Full Text] [Related]
30. Non-melanoma skin cancer: new and future synthetic drug treatments.
Amaral T; Garbe C
Expert Opin Pharmacother; 2017 May; 18(7):689-699. PubMed ID: 28414587
[TBL] [Abstract][Full Text] [Related]
31. Roles of white blood cells and subtypes as inflammatory markers in skin cancer.
Baykan H; Cihan YB; Ozyurt K
Asian Pac J Cancer Prev; 2015; 16(6):2303-6. PubMed ID: 25824754
[TBL] [Abstract][Full Text] [Related]
32. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
33. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
[TBL] [Abstract][Full Text] [Related]
34. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
35. Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults.
Ferrante di Ruffano L; Dinnes J; Chuchu N; Bayliss SE; Takwoingi Y; Davenport C; Matin RN; O'Sullivan C; Roskell D; Deeks JJ; Williams HC;
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD013187. PubMed ID: 30521689
[TBL] [Abstract][Full Text] [Related]
36. Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers.
Komatsubara KM; Jeter J; Carvajal RD; Margolin K; Schadendorf D; Hauschild A
Am Soc Clin Oncol Educ Book; 2017; 37():641-650. PubMed ID: 28561682
[TBL] [Abstract][Full Text] [Related]
37. Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage.
Zhu GA; Sundram U; Chang AL
JAMA Dermatol; 2014 Sep; 150(9):970-3. PubMed ID: 24740281
[TBL] [Abstract][Full Text] [Related]
38. Basal cell carcinoma-associated paratumoral follicular and epidermal hyperplasia.
Abenoza P; Kowalczyk J; Nousari CH
Am J Dermatopathol; 2010 Jun; 32(4):348-51. PubMed ID: 20145534
[TBL] [Abstract][Full Text] [Related]
39. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
[TBL] [Abstract][Full Text] [Related]
40. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.
Bhutani T; Abrouk M; Sima CS; Sadetsky N; Hou J; Caro I; Chren MM; Arron ST
J Am Acad Dermatol; 2017 Oct; 77(4):713-718. PubMed ID: 28780365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
